Blog Archives

Dabrafenib/Trametinib-Combo approved for BRAF-positive anaplastic thyroid cancer

 

May 05, 2018 – The American Food and Drug Administration (FDA) just approved the combination of Dabrafenib (Tafinlar)/Trametinib (Mekinist) to be administered together for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic),

Read more ›

Tags: , , , , , , , , ,

Olaparib Tablets (Lynparza): For breast cancer with BRCA gene mutation

January 13, 2018 – The American Food and Drug Administration (FDA) has just approved the first treatment for breast cancer with a certain inherited genetic mutation. At first glance, this announcement may be just one in the series of announcements by the FDA on new drug approvals.

Read more ›

Tags: , , , , , , , , ,

Vemurafenib (Zelboraf) for BRAF V600E positive Erdheim-Chester Disease (ECD)

Dezember 21, 2017 – Erdheim–Chester disease ((ECD), also known as Erdheim–Chester syndrome or polyostotic sclerosing histiocytosis) is a form of a bone marrow borne blood cancer. It is a rare disease characterized by the abnormal multiplication of a specific type of white blood cells called histiocytes,

Read more ›

Tags: , , , , , , , , ,

First cancer treatment for any solid tumor with MSI-H or dMMR approved

May 24, 2917 – The American Food & Drug Administration (FDA) just approved a major extension of the clinical indications for Pembrolizumab (Keytruda). For the first time,  a cancer treatment has been approved for any solid tumor, irrespective of the tumor’s original location, as long as the targeted tumor is carrying a specific genetic feature (i.e.,

Read more ›

Tags: , , , , , , , , ,

Theragenomics: Ivacaftor (Kalydeco) in the CFTR mutation-based treatment of cystic fibrosis (CF)

May 18, 2017 – Ivacaftor (Kalydeco) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who are carriers one of the following mutations in the CFTR gene: G551D,

Read more ›

Tags: , , , , , , ,

Palbociclib (Ibrance): New treatment for advanced or metastatic breast cancer in the EU

 September 17, 2016 – Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012. In Europe, there were an estimated 464,000 new cases of breast cancer in 2012 and an estimated 131,000 deaths from the disease. Hormone receptor positive breast cancer accounts for 65% of tumours in women aged 35 to 65 years and 82% of tumours in women older than 65 years.

Read more ›

Tags: , , , , , , , , , , , , ,

Cabometyx and Kisplyx: Two new medicines for advanced kidney cancer

July 26, 2016  – Renal cell carcinoma is the most common form of kidney cancer in adults. Advanced renal cell carcinoma includes both metastatic disease and locally advanced renal cell carcinoma that cannot be removed by surgery. Despite the recent approval of new therapies for advanced renal cell carcinoma,

Read more ›

Tags: , , , , , , , ,

Daclizumab (Zinbryta) approved for the treatment of multiple sclerosis (MS)

May 28, 2016 – Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body. It is among the most common causes of neurological disability in young adults and occurs more frequently in women than men.

Read more ›

Tags: , , , , , , , ,

Nivolumab (Opdivo): Do targeted therapies diminish market volumes of drugs?

May 17, 2016 – Do targeted therapies diminish market volumes? Not necessarily, as we can nicely learn from the example of Nivolumab (Opdivo). While initially the targeted development of a drug (Nivolumob (Opdivo) in this case) may lead to a somewhat restricted use of a drug in a targeted and selected patient subgroup,

Read more ›

Tags: ,

News for Obinutuzumab (Gazyva) and Everolimus (Afinitor)

February 26, 2016 – Two new treatments for oncologic indications have been approved by the American Food and Drug Administration (FDA). Thus, the FDA approved Obinutuzumab (Gazyva) for use in combination with bendamustine followed by Obinutuzumab (Gazyva) monotherapy for the treatment of patients with follicular lymphoma (FL) who relapsed after,

Read more ›

Tags: , , , , ,

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • New study shows how cancer survivors develop opioid addictions November 22, 2019
    Opioids play an important role in how cancer patients manage pain, but the ongoing opioid epidemic has raised concerns about their potential for abuse. A new study in the Journal of the National Cancer Institute reveals that several factors are associated with a risk for persistent opioid use, including younger age, white race, unemployment at […]
  • Lack of sleep may explain why poor people get more heart disease November 22, 2019
    Insufficient sleep is one reason why disadvantaged groups have more heart disease. That's the finding of a study published today in Cardiovascular Research, a journal of the European Society of Cardiology (ESC).
  • Women raised in poor neighborhoods face an increased risk of intimate partner violence November 21, 2019
    Women who spend longer periods of their early lives in less affluent neighbourhoods are at greater risk of experiencing violence during their early adulthoods at the hands of their intimate partners, finds a new study published in Epidemiology.
  • A review of single molecule-based electronic devices November 21, 2019
    In a paper to be published in the forthcoming issue in NANO, a group of researchers from the Shenyang Jianzhu University in China provide an overview of single molecule electronic devices, including molecular electronic devices and electrode types. Future challenges are described in the hopes of attracting more experts from different fields to participate in […]
  • Wolfe Creek Crater younger than previously thought November 21, 2019
    Wolfe Creek Crater, one of the world's largest meteorite craters, is much younger than previously thought.
Top